Beta Drugs Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Beta Drugs Ltd is ₹ 1320 as of 05 May 15:30 . The P/E Ratio of Beta Drugs Ltd changed from 9.8 on March 2021 to 45.3 on March 2025 . This represents a CAGR of 35.82% over 5 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of Beta Drugs Ltd changed from ₹ 115.37 crore on March 2021 to ₹ 1923 crore on March 2025 . This represents a CAGR of 75.55% over 5 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of Beta Drugs Ltd for the Dec '25 is ₹ 89.58 crore as compare to the Sep '25 revenue of ₹ 106.37 crore. This represent the decline of -15.78% The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The ebitda of Beta Drugs Ltd for the Dec '25 is ₹ 19.3 crore as compare to the Sep '25 ebitda of ₹ 24.3 crore. This represent the decline of -20.58% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The net profit of Beta Drugs Ltd changed from ₹ 8.95 crore to ₹ 8.52 crore over 5 quarters. This represents a CAGR of -3.86% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The Dividend Payout of Beta Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About Beta Drugs Ltd

Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005.
Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group.
Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India.
The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers.
The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Beta Drugs Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Beta Drugs Ltd or Medicamen Biotech Ltd?

Market cap of Beta Drugs Ltd is 1,338 Cr while Market cap of Medicamen Biotech Ltd is 379 Cr

What are the key factors driving the stock performance of Beta Drugs Ltd and Medicamen Biotech Ltd?

The stock performance of Beta Drugs Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Beta Drugs Ltd and Medicamen Biotech Ltd?

As of May 5, 2026, the Beta Drugs Ltd stock price is INR ₹1320.0. On the other hand, Medicamen Biotech Ltd stock price is INR ₹280.1.

How do dividend payouts of Beta Drugs Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Beta Drugs Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.